The microtubule depolymerizing agent CYT997 effectively kills acute myeloid leukemia cells via activation of caspases and inhibition of PI3K/Akt/mTOR pathway proteins
Open Access
- 14 June 2013
- journal article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 6 (2), 299-304
- https://doi.org/10.3892/etm.2013.1161
Abstract
The orally active microtubule-depolymerizing agent CYT997 is potently cytotoxic to a variety of tumors in vitro and in vivo. However, the effects of this agent on acute myeloid leukemia (AML) cells and its mechanisms are unknown. The present study demonstrated that CYT997 effectively inhibited the growth of AML cells in vitro. Treatment of AML cells with CYT997 resulted in G2/M phase cell cycle arrest, and induced apoptosis through the activation of extrinsic and intrinsic apoptotic pathways. Furthermore, CYT997 induced cell death in CD123+ leukemia cells and significantly reduced leukemia colony formation. CYT997 was also demonstrated to exert dual effects on the expression of PI3K/Akt and mechanistic target of rampamycin (mTOR) signaling pathway proteins. Therefore, CTY997, used alone or in combination with chemotherapy, may represent a promising approach for the treatment of AML.Keywords
This publication has 24 references indexed in Scilit:
- The microtubule targeting agent PBOX-15 inhibits integrin-mediated cell adhesion and induces apoptosis in acute lymphoblastic leukaemia cellsInternational Journal of Oncology, 2012
- The Microtubule Depolymerizing Agent CYT997 Causes Extensive Ablation of Tumor Vasculature In VivoThe Journal of pharmacology and experimental therapeutics, 2011
- Microtubule-targeted agents: When mitochondria become essential to chemotherapyBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2011
- CYT997 Causes apoptosis in human multiple myelomaInvestigational New Drugs, 2009
- CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivoMolecular Cancer Therapeutics, 2009
- Discovery of CYT997: a structurally novel orally active microtubule targeting agentBioorganic & Medicinal Chemistry Letters, 2009
- The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell deathBlood, 2008
- STI-571 (Imatinib Mesylate) Enhances the Apoptotic Efficacy of Pyrrolo-1,5-Benzoxazepine-6, a Novel Microtubule-Targeting Agent, in Both STI-571-Sensitive and -Resistant Bcr-Abl-Positive Human Chronic Myeloid Leukemia CellsThe Journal of pharmacology and experimental therapeutics, 2007
- Current State of the Art of New Tubulin Inhibitors in the ClinicCurrent Clinical Pharmacology, 2006
- The molecular pathogenesis of acute myeloid leukemiaCritical Reviews in Oncology/Hematology, 2005